Ergoteles’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ergoteles’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,359	Closed	-$217K	–	1496
2022 Q4	$217K	Sell	1,359 -17,196	-93%	-$2.52M	0.01%	1043
2022 Q3	$2.47M	Buy	+18,555	New	+$2.82M	0.09%	228
2022 Q2	–	Sell	-1,452	Closed	-$226K	–	1822
2022 Q1	$226K	Sell	1,452 -1,528	-51%	-$222K	0.01%	940
2021 Q4	$380K	Buy	+2,980	New	+$392K	0.01%	759
2021 Q1	–	Sell	-2,200	Closed	-$363K	–	928
2020 Q4	$363K	Buy	+2,200	New	+$328K	0.01%	500

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ergoteles's JAZZ Position: Q1 2023 in Review

Ergoteles sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 1,359 shares — an estimated $217K sold.

Ergoteles first reported a position in JAZZ in Q4 2020 and held it in 5 quarters. The position peaked at $2.47M in Q3 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Ergoteles reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,359 Jazz Pharmaceuticals shares in Q1 2023, an estimated $217K.
Ergoteles first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Ergoteles's Jazz Pharmaceuticals position peaked at $2.47M in Q3 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.